Reata Pharmaceuticals competitorsClear all

Reata Pharmaceuticals's top competitors include Aimmune Therapeutics, MyoKardia, Otonomy and Vertex Pharmaceuticals.
Reata Pharmaceuticals
Reata Pharmaceuticals
Reata Pharmaceuticals is a biopharmaceutical company focused on translating innovative science into breakthrough medicines for intractable diseases.
Aimmune Therapeutics
Aimmune Therapeutics
Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies.
MyoKardia
MyoKardia
MyoKardia discovers, develops and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.
Otonomy
Otonomy
Otonomy is a biopharmaceutical company developing and commercializing treatments for diseases of the inner and middle ear.
Vertex Pharmaceuticals
Vertex Pharmaceuticals
Vertex Pharmaceuticals is focused on the discovery and development of small molecule drugs for the treatment of serious diseases.
Founding Date
Founding Date
2002
Founding Date
2011
Founding Date
2012
Founding Date
2008
Founding Date
1989
Type
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
Plano, US HQ
Irving, US
Plano, US
Locations
Brisbane, US HQ
München, DE
Dublin, IE
London, GB
Durham, US
Locations
South San Francisco, US HQ
Brisbane, US
Locations
San Diego, US HQ
Locations
Boston, US HQ
St Leonards, AU
Wien, AT
Toronto, CA
see more
Employees
Employees
22079% increase
Employees
2755% increase
Employees
23542% increase
Employees
49
Employees
3,00020% increase
Valuation ($)
Valuation ($)
3.9 b
Valuation ($)
2.3 b
Valuation ($)
12 b
Valuation ($)
193.4 m
Valuation ($)
58.6 b
Twitter followers
Twitter followers
1.1 k
Twitter followers
1.6 k
Twitter followers
1.2 k
Twitter followers
214
Twitter followers
65.2 k
Number of tweets (last 30 days)
Number of tweets (last 30 days)
14
Number of tweets (last 30 days)
1
Number of tweets (last 30 days)
N/A
Number of tweets (last 30 days)
N/A
Number of tweets (last 30 days)
5
Average likes per tweet (last 30 days)
Average likes per tweet (last 30 days)
4.6
Average likes per tweet (last 30 days)
8
Average likes per tweet (last 30 days)
N/A
Average likes per tweet (last 30 days)
N/A
Average likes per tweet (last 30 days)
30.2
Percentage of tweets with engagement (last 30 days)
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
100%
Alexa Website Rank
Alexa Website Rank
283162
Alexa Website Rank
193253
Alexa Website Rank
239431
Alexa Website Rank
339305
Alexa Website Rank
145684
Employee Rating
Employee Rating
3.9
Employee Rating
4.3
Employee Rating
4.2
Employee Rating
4.3
Employee Rating
3.4

Financial

Revenue (est.)
Revenue (est.)
$26.5m (FY, 2019)
Revenue (est.)
N/A
Revenue (est.)
N/A
Revenue (est.)
$600k (FY, 2019)
Revenue (est.)
$4.2b (FY, 2019)
Cost of goods
Cost of goods
N/A
Cost of goods
N/A
Cost of goods
N/A
Cost of goods
$912k (FY, 2019)
Cost of goods
$547.8m (FY, 2019)
Gross profit
Gross profit
N/A
Gross profit
N/A
Gross profit
N/A
Gross profit
($312k) (FY, 2019)
Gross profit
$3.6b (FY, 2019)
Net income
Net income
($290.2m) (FY, 2019)
Net income
($248.5m) (FY, 2019)
Net income
($276.2m) (FY, 2019)
Net income
($44.7m) (FY, 2019)
Net income
$1.2b (FY, 2019)

Operating

Patents Issued
Patents Issued
240 (FY, 2016)
Patents Issued
2 (FY, 2016)
Patents Issued
N/A
Patents Issued
88 (FY, 2016)
Patents Issued
N/A
Patents Pending
Patents Pending
280 (FY, 2016)
Patents Pending
N/A
Patents Pending
N/A
Patents Pending
115 (FY, 2016)
Patents Pending
N/A
Phase I Trials Products
Phase I Trials Products
2 (FY, 2016)
Phase I Trials Products
N/A
Phase I Trials Products
1 (FY, 2018)
Phase I Trials Products
1 (FY, 2016)
Phase I Trials Products
N/A
Phase II Trials Products
Phase II Trials Products
4 (FY, 2016)
Phase II Trials Products
N/A
Phase II Trials Products
2 (FY, 2018)
Phase II Trials Products
2 (FY, 2016)
Phase II Trials Products
N/A
Phase III Trials Products
Phase III Trials Products
1 (FY, 2016)
Phase III Trials Products
N/A
Phase III Trials Products
1 (FY, 2018)
Phase III Trials Products
2 (FY, 2016)
Phase III Trials Products
N/A
Pre-Clinical Phase Products
Pre-Clinical Phase Products
N/A
Pre-Clinical Phase Products
N/A
Pre-Clinical Phase Products
3 (FY, 2018)
Pre-Clinical Phase Products
1 (FY, 2016)
Pre-Clinical Phase Products
N/A

Funding

Total funding raised
Total funding raised
$ 468.9m
Total funding raised
$ 145m
Total funding raised
$ 98m
Total funding raised
$ 153.4m
Total funding raised
$ 2.4m
For sources of this data, please see the company profile

View company profiles

Aimmune Therapeutics
HQ
Brisbane, US
Employees
275↑ 5% increase

Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies.

View company
MyoKardia
HQ
South San Francisco, US
Employees
235↑ 42% increase

MyoKardia discovers, develops and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.

View company
Otonomy
HQ
San Diego, US
Employees
49

Otonomy is a biopharmaceutical company developing and commercializing treatments for diseases of the inner and middle ear.

View company
Vertex Pharmaceuticals
HQ
Boston, US
Employees
3,000↑ 20% increase

Vertex Pharmaceuticals is focused on the discovery and development of small molecule drugs for the treatment of serious diseases.

View company